Cadherin-17 / CDH17 (MSVA-517M)

Mouse monoclonal / Mouse IgG2b, kappa 1:100 – 1:200 Research Use Only Cell Surface and Cytoplasmic Human MSVA-517M BILL-cadherin; Cadherin-17; CDH17; HPT-1 cadherin; human intestinal peptide-associated transporter HPT-1; human peptide transporter 1 (HPT-1); Intestinal peptide-associated transporter HPT-1; LI-cadherin (liver-intestine); Liver Cadherin; Liver-intestine cadherin Colon: A strong CDH17 staining should be seen in all epithelial cells. Colon: Non-epithelial cells should not show any CDH17 immunostaining. Cadherin-17 (CDH17) is a 92,2 kDa protein coded by the CDH17 gene on chromosome 8q22.1. As other members of the cadherin superfamily, CDH17 is a calcium-dependent, membrane-associated glycoprotein. CDH17 acts as an adhesion protein and has a role as a proton-dependent peptide transporter. CDH17 is involved in absorption of various peptide-based drugs. CDH17 was also suggested to be relevant for the morphological organization of liver and intestine. In cancer, aberrant CDH17 expression was found to be linked to unfavorable tumor features in several cancer entities. Cadherin-17 (CDH17) is a 92,2 kDa protein coded by the CDH17 gene on chromosome 8q22.1. As other members of the cadherin superfamily, CDH17 is a calcium-dependent, membrane-associated glycoprotein. CDH17 acts as an adhesion protein and has a role as a proton-dependent peptide transporter. CDH17 is involved in absorption of various peptide-based drugs. CDH17 was also suggested to be relevant for the morphological organization of liver and intestine. In cancer, aberrant CDH17 expression was found to be linked to unfavorable tumor features in several cancer entities. CDH17 staining pattern in Normal Tissues with antibody MSVA-517M (images are shown in our “ Normal Tissue Gallery ”) Brain Cerebrum Negative. Cerebellum Negative. Endocrine Tissues Thyroid Negative. Parathyroid Negative. Adrenal gland Negative. Pituitary gland Negative. Respiratory system Respiratory epithelium Negative. Lung Negative. Gastrointestinal Tract Salivary glands Negative. Esophagus Negative. Stomach Negative. Duodenum Strong membranous, predominantly basolateral CDH17 staining of all epithelial cells. Small intestine Strong membranous, predominantly basolateral CDH17 staining of all epithelial cells. Appendix Strong membranous, predominantly basolateral CDH17 staining of all epithelial cells. Colon Strong membranous, predominantly basolateral CDH17 staining of all epithelial cells. Rectum Strong membranous, predominantly basolateral CDH17 staining of all epithelial cells. Liver Negative. Gallbladder A focal CDH17 staining of variable intensity is often seen in epithelial ce... A positive CDH17 immunostaining can be seen in a large fraction of adenocarcinomas derived from the colorectum, stomach, and the esophagus. Several other tumor entities are known to at least occasionally express CDH17. These include adenocarcinoma of the pancreas, mucinous ovarian cancer, cancers of the female genital tract and others. The TCGA findings on CDH17 RNA expression in different tumor categories have been summarized in the Human Protein Atlas. Gastric adenocarcinoma (intestinal type) exhibiting a strong CDH17 immunostaining of all tumor cells CDH17 negative adenocarcinoma. Adenocarcinoma showing strong CDH17 immunostaining of tumor cells. Cancer tissue gallery Cadherin-17 ( MSVA-517M) publication summary Relevant publication: Jacobsen et al. “ Cadherin-17 (CDH17) expression in human cancer: A tissue microarray study on 18,131 tumors” Published Pathol Res Pract. 2024 Apr;256:155175. Epub 2024 Jan 28. PMID: 38452580. A total of 14,948 tumors were successfully analyzed from 150 different tumor categories by using the following protocol: Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7,8 Target Retrieval Solution buffer. MSVA-517M at a dilution of 1:150 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent). This protocol was also used for all stainings depicted in our tumor and normal tissue galleries. Overall, 53 of 150 tumor categories showed detectable CDH17 expression in at least one case and 26 tumor categories included at least one case with strong CDH17 positivity. The highest rate of positive staining was found in epithelial and neuroendocrine neoplasms of the colorectum ... IHC users have different preferences on how the stains should look like. Some prefer high staining intensity of the target stain and even accept some background. Others favor absolute specificity and lighter target stains. Factors that invariably lead to more intense staining include higher concentration of the antibody and visualization tools, longer incubation time, higher temperature during incubation, higher temperature and longer duration of the heat induced epitope retrieval (slide pretreatment). The impact of the pH during slide pretreatment has variable effects and depends on the antibody and the target protein. All images and data shown here and in our image galleries are obtained by the manual protocol described below. Other protocols resulting in equivalent staining are described as well. Manual protocol Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7,8 Target ... The diagnostic utility of CDH17 IHC should be investigated in a large cohort containing as many as possible tumors from as many as possible different entities. The clinical significance of CDH17 expression levels in gastrointestinal tumors deserves further investigation. There are two ways how the specificity of antibodies can be documented for immunohistochemistry on formalin fixed tissues. These are: 1. Comparison with a second independent method for target expression measurement across a large number of different tissue types (orthogonal strategy), and 2. Comparison with one or several independent antibodies for the same target and showing that all positive staining results are also seen with other antibodies for the same target (independent antibody strategy). Orthogonal validation: For the antibody MSVA-517M specificity is suggested by the strong concordance of the immunostaining data with data from three independent RNA screening studies, including the Human Protein Atlas (HPA) RNA-seq tissue dataset, the FANTOM5 project, and the Genotype-Tissue Expression (GTEx) project, which are all summarized in the Human Protein Atlas (Tissue expression CDH17) . RNA expression largely predominated in colorectum, small intestine, duodenum, and the appendix, t...